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ABSTRACT 
Background and Significance 
 Over 21M units of blood are transfused every year, making blood transfusion one of the 
most common medical interventions in the US. It can be lifesaving, but like many medical 
interventions, it is not without risks. Thus, most of transfusion research has focused on making 
the process safer and more accessible. 
 Recent developments in stem cell science – where the transfusion of young blood was 
shown to reverse stem cell aging and improve physiological function in older mice and 
conversely, the transfusion of old blood was shown to accelerate stem cell aging and worsen 
physiological function in younger mice – raise important questions regarding the content of 
blood being transfused and its associated risks and/or benefits. 
Research Question 
Do blood donor demographics such as age and sex affect outcomes in adult transfusion 
recipients in the intensive care unit (ICU)?  
Methods 
 This is a multi-center retrospective review examining the relationship between blood 
donor demographics such as age and sex and outcomes in adult ICU patients aged at least 18 
years who received at least one unit (u) of packed red blood cells (pRBC) or plasma or platelets 
within the first 72 hours of admission. The outcomes of interest are: mortality rate, number of 
intensive care unit (ICU) days, and hospital length of stay (LOS) days. IRB approval was obtained 
from BHS on December 11, 2018. 
Analysis was performed on the average donor age and the average donor sex (where 
male=1, female=0) against the specified patient outcome measures. Logistic regression was 
done to ascertain odds of mortality. Linear regression was done to ascertain prediction for ICU 
and LOS days. 
 
Results 
 A total of 12,134 adult ICU patient records that corresponded to 65,003 blood donations 
were included in the analysis. There is no significant association between donor age and donor 
sex and mortality rate (p=0.74 and 0.59, respectively), number of ICU days (p=0.65 and 0.92, 
respectively), and hospital LOS (p=0.15 and 0.58, respectively). 
Conclusions 
 The overall trend is that there is no association between donor age and sex with 
mortality, ICU days and hospital LOS in adult ICU patients. However, the study has a limited 
sample size and is underpowered (n=12,134 vs n=15,252). Conflicting findings among similar 
studies highlight the importance of taking into account the characteristics of both the donor 
and the recipient in the analysis.  
Future prospects include determining the relationship between the recipient-donor age 
differential and patient outcomes. Subset analyses for each of the blood product types should 
be done since the number of units of specific blood product types impacts outcomes. 
Additionally, excluding outliers (i.e. extremely long ICU or hospital stays) may reveal small 
differences in outcomes (i.e. shortening ICU admission by 1 day).  
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INTRODUCTION 
Over 21M units of blood are transfused every year, making blood transfusion one of the 
most common medical interventions in the US.1  It can be a lifesaving intervention, but it is not 
without risks. Like with most medical interventions, adverse reactions are well-documented. 
Fortunately, since the first successful whole blood transfusion in the 1960’s, transfusion 
medicine has come a long way to make the process safer and more accessible. 
Recent developments in stem cell science – where age-dependent factors circulating in 
the blood have been found to influence stem cell aging and physiological function in 
heterochronic parabiosis (HP) mouse models – raise important questions regarding the 
relationship between blood donor age and recipient outcomes.  
In HP, two mice of different ages are stitched together at the skin such that their blood 
supplies are linked. Through the years, HP experiments have been shown to reverse stem cell 
aging in multiple tissue types.2-6 These results were replicated by transfusing aged mice with 
plasma from young mice.7 Furthermore, the injection of GDF-11, a circulating factor in the 
blood that is found in higher levels in young mice, has been shown to improve strength and 
endurance exercise capacity recovery from muscle injury8 as well as to promote neurogenesis 
and improve olfactory discrimination in aging mice.9 These studies provide evidence that 
factors circulating in the blood have the capability to modulate the function of stem cells and 
reverse the aging process. 
The purpose of this retrospective study is to examine whether blood transfusions from 
younger donors yield mortality benefits in humans. Our hypothesis is that patients receiving 
blood from younger donors of the same sex have improved overall survival, and shorter 
hospital and ICU stays. 
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RESEARCH METHODS AND MATERIALS 
Study Design and Outcomes 
 This is a multi-center retrospective review across 19 hospitals within the Banner Health 
System (BHS) examining the relationship between blood donor demographics such as age and 
sex and outcomes in adult ICU patients who received at least one unit (u) of packed red blood 
cells (pRBC) or plasma or platelets between January 1, 2003 and January 1, 2018. The outcomes 
of interest are: mortality rate, number of intensive care unit (ICU) days, and hospital length of 
stay (LOS) days. IRB approval was obtained from BHS on December 11, 2018. 
Sample Population 
Inclusion Criteria 
The sample population consists of all adult (18 years and above) patients (also referred 
to as recipients) who were admitted to the ICU for at least part of their hospital admission and 
who received at least one unit of pRBC or plasma or platelets within the first 72 hours of their 
admission to any one of the following Banner Health Hospitals: Banner University Medical 
Center – Phoenix, Banner University Medical Center – Tucson, Banner Estrella Medical Center, 
Banner Gateway/ M.D. Anderson Medical Center, Banner Desert/ Cardon’s Children’s Medical 
Center, Banner Thunderbird Medical Center, Banner Boswell Medical Center, Banner Baywood 
Medical Center, Banner Ironwood Medical Center, Banner Del E Webb Medical Center, Banner 
Heart Hospital, Banner Goldfield Medical Center, Banner Casa Grande Medical Center, Banner 
Payson Medical Center, and Banner University Medical Center – South Campus. The transfused 
blood product must have been supplied by Vitalant. 
Exclusion Criteria 
 The following were excluded from the study: patients with incorrect or incomplete 
records, and patients who received blood from donors with incorrect or incomplete records. 
 
 
3 
 
Data Collection 
 Data was obtained via the Honest Broker Clinical Research Data Warehouse (CRDW) of 
Banner University Medical Center Phoenix. Transfusion recipient data (age, sex, race, 
transfusion history, number of ICU days, and hospital LOS) was obtained from the Electronic 
Health Records and the Electronic Data Warehouse of BHS. The Donor Identification Number 
(DIN) for each transfusion was then used to obtain donor data (age, sex, donation date) from 
Vitalant. This was then merged with the transfusion recipient data and de-identified by honest 
broker staff for analysis. 
Data Analysis 
 Analysis was performed on the average donor age and the average donor sex (where 
male=1, female=0) against the specified patient outcome measures. Logistic regression was 
done to ascertain odds of mortality. Linear regression was done to ascertain prediction for ICU 
and LOS days. All statistical analyses were done using STATA version 14 (STATAcorp; College 
Station, TX). 
Power Calculation 
 If the difference in the proportion of mortality is 20%, 186 patients per year-increment 
(spanning from 18-100 years of age) are needed to render a statistical power of 80% with an 
alpha of 0.05; thus requiring at least 15,252 patients. 
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RESULTS 
Sample Population  
 Over the study period, 24,544 ICU patients received at least one unit of blood (pRBC or 
plasma or platelets). Of these, 12,134 (49.4%) were adult ICU patients (18 years old and up) 
who received at least one unit of blood (pRBC or plasma or platelets) within the first 72 hours 
of admission. Of these, 56.24% were male and 43.76% were female. The mean patient age was 
65.26 years (SD 16.35) (Table 1). 
On average, each patient received 2.86u pRBC (SD 4.17), 1.88u plasma (SD 4.73), and 
0.63u platelets (SD 1.65). The overall mortality rate was 15.21% (n=1,846) and the average 
number of days in the ICU and in the hospital were 3.33 (SD 11.21) and 8.88 (SD 7.97), 
respectively (Table 1).  
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Table 5. Characteristics and demographics of the patient and donor populations. 
Variables Value 
Patient Demographics (n=12,134)  
Age, years (mean, SD) 65.26 (16.35) 
Sex (male, %) 6,824 (56.24) 
  
Donor Demographics (n=65,003)  
Age, years (mean, SD) 44.85 (12.25) 
Sex (mean, SD) 0.65 (0.32) 
             Male, n (%) 42,481 (65.35) 
             Female, n (%) 22,522 (34.65) 
  
Total Transfused Units per Patient  
pRBC, units (mean, SD) 2.86 (4.17) 
Plasma, units (mean, SD) 1.88 (4.73) 
Platelets, units (mean, SD) 0.63 (1.65) 
  
Outcomes  
ICU days (mean, SD) 3.33 (11.21) 
Length of Stay, days (mean, SD) 8.88 (7.97) 
Mortality (yes, %) 1,846 (15.21) 
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Blood Donor Population  
 Over the study period, there was a total of 154,443 blood donations, 129,031 (83.55%) 
of which matched Vitalant records. For the analysis, 65,003 (42.09%) blood donations satisfied 
the inclusion criteria. The mean donor age was 44.85 years (SD 12.25) with 65.4% of donors 
being male and 34.6% female (Table 1).  
Outcomes 
Mortality 
 There is no significant association between donor age or sex and mortality rate (p=0.74 
and 0.59, respectively). The following were found to increase the likelihood of mortality: 
recipient age (OR 1.01, p<0.001), pRBC units (OR 1.03, p<0.001), plasma units (OR 1.06, 
p<0.001), and platelet units (OR 1.03, p=0.04). Recipient gender had no association with 
mortality (OR 0.91, p=0.065) (Table 2). 
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Table 6. Factors associated with mortality risk. 
Variables OR (95% CI) P-value 
Recipient Age 1.01 (1.00, 1.01) <0.001 
Recipient Gender 0.91 (0.82, 1.01) 0.065 
Average Donor Age 1.00 (0.99, 1.00) 0.748 
Average Donor Gender 1.05 (0.89, 1.23) 0.596 
Total Plasma 1.06 (1.05, 1.08) <0.001 
Total Platelets 1.03 (1.00, 1.07) 0.040 
Total RBC 1.03 (1.02, 1.05) <0.001 
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Since increasing patient age and length of stay in the ICU or the hospital are typically 
associated with increased mortality, we also examined the relationship of these variables with 
mortality. There was a significant difference in the patient age and hospital LOS between 
patients who survived and expired (p=0.03 and <0.001, respectively). There was no significant 
difference in the number of ICU days between patients who survived and expired (p=0.18) 
(Figure 1).   
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Figure 3. Comparison of mortality groups based on patient age (left), and ICU and hospital length 
of stay (right). Legend: Line- median; box- second and third quartiles; lower whisker to bottom 
box border- first quartile; bottom box border to line- second quartile; line to upper box border- 
third quartile; upper box border to upper whisker- fourth quartile; diamonds- outliers. 
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ICU Length of Stay 
There is no significant association between donor age or sex and length of ICU stay (β 
0.004, p=0.65; and β 0.034, p=0.92, respectively). The following were found to be associated 
with more ICU days: pRBC units (β 0.15, p<0.001), and platelet units (β 0.24, p=0.001). Recipient 
age and gender were not associated with ICU length of stay (β-0.003, p=0.59; and β=0.237, 
p=0.25, respectively) (Table 3). 
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Outcome Variable Beta (95% CI) p-value 
ICU LOS 
Recipient Age -0.003 (-0.02, 0.009) 0.595 
Recipient Gender 0.237 (-0.16, 0.64) 0.249 
Average Donor Age 0.004 (-0.013, 0.02) 0.652 
Average Donor 
Gender 0.034 (-0.60, 0.66) 0.922 
Total Plasma 0.034 (-0.01, 0.08) 0.172 
Total Platelets 0.242 (0.10, 0.38) 0.001 
Total RBC 0.147 (0.09, 0.21) <0.001 
Table 7. Factors associated with ICU length of stay. 
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Hospital Length of Stay 
 There is no significant association between donor age or sex and hospital LOS (β -0.008, 
p=0.15; and β 0.122, p=0.58, respectively). The following were found to be associated with a 
longer hospital LOS: recipient age (β -0.016, p<0.001), pRBC units (β 0.29, p<0.001), plasma 
units (β 0.06, p=0.001), and platelet units (β 0.39, p<0.001). Recipient gender was not 
associated with hospital LOS (β 0.264, p=0.064) (Table 4). 
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Outcome Variable Beta (95% CI) p-value 
Hospital LOS 
Recipient Age -0.016 (-0.02, -0.007) <0.001 
Recipient Gender 0.264 (-0.02, -0.54) 0.064 
Average Donor Age -0.008 (-0.02, 0.003) 0.145 
Average Donor 
Gender 0.122 (-0.31, 0.56) 0.581 
Total Plasma 0.056 (0.02, 0.09) 0.001 
Total Platelets 0.391 (0.29, 0.49) <0.001 
Total RBC 0.294 (0.25, 0.34) <0.001 
Table 8. Factors associated with hospital length of stay. 
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DISCUSSION 
Sample Population 
 In this initial analysis, there were 10 patients whose ages were above 100 years with a 
maximum value of 128 years. According to the 2010 US Census Report, there are approximately 
1.73 centenarians per 10,000 in the US.10 While it is possible that some of the patients in the 
sample are centenarians –it is more likely that these are either clerical errors or unknown 
values and should be excluded in future analyses. 
Donor Population 
 In terms of age distribution, the donor population of the study closely resembles the 
national donor population except for an increased proportion of donors over 65 years of age 
(Figure 2). This means that if there were any risks associated with older donors, this study 
would magnify those effects. There is no published data on the sex distribution of blood donors 
in the US. 
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Figure 4. Comparison of blood donor age distribution at the Banner Health System (2003-2018) 
versus US statistics by the World Health Organization (2008).11 
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Study Outcomes 
Donor Age and Outcomes 
There is no association between donor age with mortality, ICU LOS and hospital LOS in 
adult ICU patients. A few retrospective studies investigating the relationship between donor 
age and recipient outcomes have had similar results.  
The first study used national data on pRBC and plasma transfusion recipients (n=45,664 
and n=136,639, respectively) from the Scandinavian Donations and Transfusions Database 
(SCANDAT2) and found no association between donor age (ie, as <25, 25-50, >50 years) and 30-
day and 1-year mortality.1 However, the analysis only considered the first 7 days of transfusions 
which discounts all other exposures. Following this, a study out of Duke University found no 
association between pRBC donor age (ie, as 17-37, 38-50, 51-86 years) and patient mortality, 
LOS and acute kidney injury (AKI) rates in patients receiving plasma perioperatively for coronary 
artery bypass grafting surgery (n=1,306).2  
The discordance of these results with mouse studies has been attributed to inadequate 
exposure in terms of dose and duration. In HP, half of the older mouse’s blood supply is from 
the young mouse, while the median number of units transfused were 2.86, 1.88, and 0.63 for 
pRBC, plasma and platelets, respectively for an estimated total volume of 1.7L. This roughly 
corresponds to about 34% of the 5-liter total blood supply of an average sized man (70kg). 
Furthermore, transfused blood products typically have a shorter effective lifespan than native 
blood due to biochemical changes during storage.12 
However, a Canadian retrospective study (n=30,503) looking at cumulative pRBC 
transfusions over time did show an increased risk of death with younger donors compared to 
donors in the 40-49.9-year old range (adjusted hazard ratio (AHR) 1.08, p <0.001 for age range 
17-19.9 years; and AHR 1.06, p<0.001 for age range 20-29.9 years).3 These findings contradict 
those from mouse models4 and have been attributed to the healthy donor phenomenon.5 This 
is a well-documented phenomenon in transfusion literature and is due to the fact that older 
individuals that are eligible to donate blood are generally healthier and have had more 
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encounters with the healthcare system whereas younger individuals may simply be 
asymptomatic from undiagnosed medical conditions. 
Following this, a study using the methodology of the Canadian study on SCANDAT2 data 
(n=968,264) showed no association between donor age and sex with survival in patients 
receiving pRBC tranfusions.6 Differences in patient population may account for the conflicting 
results (i.e., median recipient age 73 versus 69 years for the Scandinavian and the Canadian 
studies, respectively).  
Donor Sex and Outcomes 
 While our study did not show any association between donor sex and patient outcomes, 
the evidence behind the role of female donor plasma in the development of transfusion-related 
acute lung injury (TRALI), the leading cause of transfusion-related mortality, has grown in recent years. 
A large prospective, case-controlled study of TRALI showed decreased TRALI rates after 
reduction of transfusion of plasma from female donors.13 This was attributed to the transfusion of 
reduced amounts of cognate HLA class II antibodies14 and HNA antibodies15 which have been shown to 
increase the risk of TRALI. These leukocyte antibodies are formed after exposure to their respective 
antigens through prior pregnancy, transfusion, or transplantation. Multiparous women, specifically, 
have been found to undergo anti-HLA and anti-HNA alloimmunization at higher frequencies.16 
Transfusion and transplant recipients are typically not eligible for blood donation17 and thus would not 
affect transfusion outcomes.  
Other Factors and Outcomes 
Perhaps the association of recipient age and number of units transfused with mortality, 
ICU days and hospital LOS are due to overall health status as well as the indication for the 
transfusion and its severity. 
Limitations 
Because of the retrospective design of our study, our data is limited to what has been 
documented by BHS and Vitalant staff. It is possible that we may have missed mortalities 
because the patient expired outside of their admission and had no further encounters within 
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BHS. There is also a significant amount of records that had to be excluded due to incomplete or 
incorrect data points within the BHS electronic health record (EHR) and the Vitalant database. 
This initial analysis was done in a broad population of adult ICU patients with numerous 
potential confounding factors such as nature and severity of primary disease, comorbidities, 
and indication for transfusion and no control group. Additionally, outliers were included in the 
analysis (ie, extremely high recipient age, and long hospital and ICU stays) which may have 
masked smaller effects on outcomes (ie, shortening ICU admission by 1 day).  
It is possible that our study was underpowered (n=12,134 versus n=15,252 based on 
power calculation; however, any clinical relevance should have been uncovered in the second 
SCANDAT2 study given its sample size of 968,264.  
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FUTURE DIRECTIONS 
The discrepancies between our findings and those of the Canadian and Scandinavian 
studies highlight the importance of taking into account the characteristics of both the donor 
and the recipient in the analysis. Future prospects include determining the relationship 
between the recipient:donor age differential and/or recipient:donor sex dyad (ie, M:M, M:F, 
F:F, and F:M) and patient outcomes.  
Subset analyses for each of the blood product types should be done since the number of 
units of specific blood product types impacts outcomes. Additionally, excluding outliers (i.e. 
extremely long ICU or hospital stays) may reveal small differences in outcomes (i.e. shortening 
ICU admission by 1 day). 
Since both mortality and length of stay are influenced by many factors, sometimes 
including hospital logistics, the lack of association between donor demographics and patient 
mortality and length of stay does not preclude the possibility of an association with more fine-
grained outcomes such as rates of transfusion reactions, acute kidney injury (AKI), myocardial 
infarction (MI), ventilator- and hospital- associated pneumonias (VAP and HAP), central line-
associated bloodstream infections (CLABSI), and catheter-associated urinary tract infections 
(CAUTI). Further analyses using these outcome measures might reveal differences between 
blood obtained from younger versus older donors. 
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CONCLUSIONS 
 There is no association between donor age and sex with mortality, ICU days and hospital 
LOS in adult ICU patients. However, the study has a limited sample size and is underpowered 
(n=12,134 vs n=15,252). Conflicting findings among similar studies highlight the importance of 
taking into account the characteristics of both the donor and the recipient in the analysis.  
Future prospects include determining the relationship between the recipient-donor age 
differential and patient outcomes (including more fine-grained outcomes such as rates of 
transfusion reactions, AKI, MI, HAP/VAP, CAUTI, CLABSI, etc). Subset analyses for each of the 
blood product types should be done since the number of units of specific blood product types 
impacts outcomes. Subset analyses on specific adult ICU populations should also be done to 
minimize confounding factors. Additionally, excluding outliers (i.e. extremely long ICU or 
hospital stays) may reveal small differences in outcomes (i.e. shortening ICU admission by 1 
day).  
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